Total
0
Shares
MyFiziq (ASX:MYQ) receives US$450,000 to progress Nasdaq listing
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Advanced Human Imaging (AHI) will run a test pilot on its CompleteScan offering in partnership with Discovery Vitality
  • The business is a subsidiary of financial services and insurance provider Discovery and its Vitality shared-value insurance model attracts over 20 million members across 28 countries
  • AHI and Discovery have spent the last year testing the ASX-lister's various medical imaging products, which can be accessed from a smartphone
  • Under this latest partnership though, Discovery will spend the month of May testing the real-time data accuracy and efficiencies of CompleteScan
  • The consumer-facing pilot will take place at four Discovery facilities in South Africa, with specialists testing AHI's results against traditional health evaluations
  • Additionally, commercial discussions are continuing between AHI and Discovery about ongoing access to the application
  • Shares in Advanced Human Imaging are trading at $1.57 per share, down 3.07 per cent

Advanced Human Imaging (AHI) has announced a consumer pilot, which is running accuracy tests on its CompleteScan offering, has gotten underway with partner Discovery Vitality.

The business is a subsidiary of financial services and insurance provider Discovery, and its Vitality shared-value insurance model attracts over 20 million members across 28 countries.

Meanwhile, Advanced Human Imaging's tech can all be accessed and used by a person from a smartphone, while CompleteScan combines all of the various medical imaging products into one platform.

Together, AHI and Discovery Vitality have spent the last year testing the ASX-lister's various medical imaging products.

Under this latest partnership, Discovery has committed to spend the month of May testing the real-time data accuracy and efficiencies of CompleteScan.

The consumer-facing pilot will take place at four Discovery facilities located across South Africa, with wellness specialists essentially testing AHI's results against traditional health evaluations.

In addition to the pilot and testing work, AHI and Discovery are in commercial discussion for the ongoing access to the application.

"The CompleteScan integration will deliver a high-quality cost-effective data set, which will have exponential value in risk assessment and management when integrated into a solution like Vitality," AHI CEO Vlado Bosanac said.

"Better health outcomes mean better quality of life. The ethos of a platform of this nature is to do exactly that, help people live better healthier lives," he added.

"This is where the CompleteScan application is most effective, by
identifying negative health indicators through actionable data for early intervention," Vlado explained.

Shares in Advanced Human Imaging are trading at $1.57 per share, down 3.07 per cent at 1:18 pm AEST.

AHI by the numbers
More From The Market Herald
Oventus Medical (ASX:OVN) - Chairman, Sue MacLeman (centre left) - The Market Herald

" Oventus Medical (ASX:OVN) eyes $5M placement to strengthen balance sheet

Sleep apnoea specialist Oventus Medical (OVN) has received firm commitments to undertake a $5 million placement.
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) commences prostate cancer clinical trial

Telix Pharmaceuticals (TLX) has been given the green light to commence a phase three clinical trial of its targeted therapy candidate TLX591 in
Bod Australia (ASX:BDA) - CEO, Jo Patterson - The Market Herald

" Bod Australia (ASX:BDA) records highest ever month of MediCabilis sales

Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.
Prescient Therapeutics (PTX) -CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) signs new research agreement with Peter MacCallum Cancer Centre

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs.